2025
An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
Spigel D, Westeel V, Anderson I, Greillier L, Guisier F, Bylicki O, Badin F, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Gubens M, Crowley J, von der Leyen H, Woodard G, Kratz J, Jablons D, Mann M. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. Journal Of Clinical Oncology 2025, 43: lba8027-lba8027. DOI: 10.1200/jco.2025.43.17_suppl.lba8027.Peer-Reviewed Original ResearchNon-small cell lung cancerDisease free survivalModified intent-to-treatAdjuvant chemotherapyCell lung cancerLung cancerInterim analysisCycles of platinum-based adjuvant chemotherapyNon-squamous non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized trials of adjuvant chemotherapyModified intent-to-treat populationTumor size > 4 cmNon-squamous NSCLC patientsRandomized to adjuvant chemotherapyTime of chemotherapy initiationMedian disease free survivalImproved disease free survivalPlatinum-based adjuvant chemotherapyTrials of adjuvant chemotherapyHigh riskRandomized to observationMedian follow-upPrimary lung cancerProspective randomized trialsDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodLobectomy vs Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation
Woodard G, Grau-Sepulveda M, Onaitis M, Udelsman B, David E, Jacobs J, Kosinski A, Blasberg J, Boffa D. Lobectomy vs Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation. The Annals Of Thoracic Surgery 2025, 119: 1071-1081. PMID: 39864772, DOI: 10.1016/j.athoracsur.2025.01.004.Peer-Reviewed Original ResearchNon-small cell lung cancerSublobar resectionCell lung cancerLung cancerNodal upstagingImproved survivalHealthy patientsNode-negative non-small cell lung cancerThe Society of Thoracic Surgeons databaseRandomized trialsSociety of Thoracic Surgeons databaseAssociated with improved survivalEarly-stage lung cancerFewer lymph nodesInferior to survivalSublobar resection groupLymph node resectionThoracic Surgeons databaseLymph node evaluationProspective randomized trialsKaplan-Meier analysisForced expiratory volumeCT1 N0Pathologic upstagingNodal evaluation
2024
The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinibLiving on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff
Udelsman B, Bedrosian C, Kawaguchi E, Ding L, Wallace W, Rosenberg G, Harano T, Wightman S, Atay S, Kim A, Woodard G. Living on the edge: Role of adjuvant therapy after resection of primary lung cancer within 2 millimeters of a T-stage cutoff. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: 1338-1345.e15. PMID: 39521371, PMCID: PMC12034478, DOI: 10.1016/j.jtcvs.2024.10.053.Peer-Reviewed Original ResearchNon-small cell lung cancerSystemic therapyOverall survivalT stageTumor sizeResected non-small cell lung cancerLung cancerNational Cancer Database of patientsResection of primary lung cancerOutcomes of systemic therapyPathologic tumor sizeNational Cancer DatabaseAdjuvant therapy useUse of systemic therapyPrimary lung cancerResection of tumorsCell lung cancerAssociated with decreased ratesDatabase of patientsRetrospective cohort studyTumor size distributionDownstaged patientsNodal involvementUnder-stagingAdjuvant therapy207 Spatial transcriptomic profiling non-small cell lung cancer reveals potential drivers of CTL exclusion and dysfunction, and identifies novel predictive biomarkers for checkpoint blockade therapy
Cho C, Lopez-Giraldez F, Huang B, He J, Woodard G, Badri T, Kidacki M, Vesely M, Wang G, Ofori-Ntiamoah G, Ng E, Chen L. 207 Spatial transcriptomic profiling non-small cell lung cancer reveals potential drivers of CTL exclusion and dysfunction, and identifies novel predictive biomarkers for checkpoint blockade therapy. 2024, a236-a236. DOI: 10.1136/jitc-2024-sitc2024.0207.Peer-Reviewed Original ResearchNon-small cell lung cancerCheckpoint blockade therapyCell lung cancerBlockade therapyPredictive biomarkersLung cancerTherapyEP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer
Ermer T, Kim S, Goldberg S, Zolfaghari E, Blasberg J, Boffa D, Herbst R, Politi K, Schalper K, Dacic S, Woodard G. EP.07C.10 Real-World Outcomes of Patients Treated with Neoadjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s543-s544. DOI: 10.1016/j.jtho.2024.09.1007.Peer-Reviewed Original Research
2023
The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant M, Woodard G, Goldberg S. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. Hematology/Oncology Clinics Of North America 2023, 37: 513-531. PMID: 37024389, DOI: 10.1016/j.hoc.2023.02.003.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerMetastatic non-small cell lung cancerResectable non-small cell lung cancerImmuno-oncology agentsHistologic classification systemUnited States FoodResectable tumorsSystemic therapyDriver alterationsDrug AdministrationStates FoodSystemic managementPatientsTherapyCancerEvolving roleClassification systemNTRKHER2TumorsKRASEGFRBRAF
2020
Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung Cancer
Hamilton B, Haro G, Woodard G, Sheu B, Kratz J, Mann M, Jablons D. Everybody Must Get Scanned? Molecular Risk Stratification May Limit the Need for CT Surveillance Following Surgical Resection of Early-Stage Non-Squamous, Non-Small Cell Lung Cancer. 2020, a7693-a7693. DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7693.Peer-Reviewed Original Research
2019
Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer
Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e1917062. PMID: 31808928, PMCID: PMC6902768, DOI: 10.1001/jamanetworkopen.2019.17062.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerTNM staging systemDisease-free survivalHigh-risk patientsCell lung cancerStaging systemEighth editionSurgical resectionLung cancerConventional TNMPrognostic classifierNonsquamous non-small cell lung cancerQuaternary care medical centerDisease-free survival ratesHigh molecular riskSurvival 3 yearsEarly-stage diseaseConventional TNM stagingCritical unmet needCohort studyPrimary outcomeConsecutive seriesTNM stagingMolecular riskConcordance index
2017
OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer
Woodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, Jahan T, Blakely C, Jones K, Mann M, Jablons D. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s320. DOI: 10.1016/j.jtho.2016.11.341.Peer-Reviewed Original Research
2016
FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid
Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Scientific Reports 2016, 6: 34022. PMID: 27677402, PMCID: PMC5039724, DOI: 10.1038/srep34022.Peer-Reviewed Original ResearchSmall cell lung cancerCell lung cancerAtypical carcinoidLung cancerTypical carcinoidNE tumorsSCLC cellsTherapeutic targetNon-small cell lung cancerDiagnostic markerLung NE tumorsNE tumor markersWorse clinical outcomesLung neuroendocrine tumorsPresence of necrosisPotential therapeutic targetNew therapeutic targetsUseful diagnostic markerNumber of mitosesBetter diagnostic criteriaFas apoptosis pathwayNE cancersClinical outcomesNeuroendocrine tumorsFAIM2 expression
2015
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas
Yue D, Li H, Che J, Zhang Y, Tolani B, Mo M, Zhang H, Zheng Q, Yang Y, Cheng R, Jin JQ, Luh TW, Yang C, Tseng HH, Giroux-Leprieur E, Woodard GA, Hao X, Wang C, Jablons DM, He B. EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLOS ONE 2015, 10: e0132134. PMID: 26132438, PMCID: PMC4488446, DOI: 10.1371/journal.pone.0132134.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCell MovementChemotherapy, AdjuvantCombined Modality TherapyCyclophosphamideDeoxycytidineDown-RegulationDoxorubicinDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionFemaleGemcitabineGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKaplan-Meier EstimateLungLung NeoplasmsMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingOrganoplatinum CompoundsPaclitaxelPneumonectomyPrognosisRNA InterferenceRNA, Small InterferingTranscription FactorsVinblastineVinorelbineConceptsLung squamous cell carcinomaSquamous cell carcinomaLung SCC patientsNon-small cell lung cancerLung SCC cellsLung SCC cell linesSCC patientsSCC cell linesAdjuvant chemotherapyCell carcinomaPredictive markerSCC cellsEMX2 expressionImproved overall survivalCurrent staging methodsTissue samplesCell lung cancerNovel prognostic markerAdjacent normal tissuesCell linesOverall survivalSurgical resectionLung cancerPatient outcomesPrognostic markerThe Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling.
Woodard GA, Jablons DM. The Latest in Surgical Management of Stage IIIA Non-Small Cell Lung Cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling. American Society Of Clinical Oncology Educational Book 2015, e435-41. PMID: 25993207, DOI: 10.14694/edbook_am.2015.35.e435.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage IIIA diseaseStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerCell lung cancerIIIA diseaseSurvival outcomesLung cancerThoracic surgeryMultiple large clinical trialsVideo-assisted thoracic surgeryMolecular profilingCurrent operative mortalityPrimary initial therapyMajority of patientsOverall survival rateBetter systemic therapyMultidisciplinary care teamLarge clinical trialsTumor molecular profilingFine-needle aspirationLong-term survivalTriple modality treatmentTumor genetic profileGenetic profile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply